Of the 25 companies receiving tax incentives in Massachusetts, 23 will add jobs outside of Boston and Cambridge. Medtronic, ...

Sales of Sanofi’s COVID-19 and flu vaccines fell 17% in the third quarter amid declining vaccination rates and pricing ...

The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...

The discontinued CAR T therapy bbT369 came to Regeneron when the pharma bought all of 2seventy bio’s pipeline assets for $5 ...

Roche has already signed several high-ticket deals this year, including the $3.5 billion acquisition of 89bio and Genentech’s ...

Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with ...

This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...

In this episode presented by Element Materials Technology, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney discuss how small ...

The deal focuses on ICT01, a monoclonal antibody being tested in acute myeloid leukemia. ImCheck is also developing assets in ...

Two patients experienced grade 3 liver enzyme elevations that were deemed related to Terns’ investigational obesity pill TERN ...

While the threat of tariffs dies down for the pharma industry, President Donald Trump is reportedly weighing a new ...

Seven in 10 U.S. hiring managers say their company usually considers employing overqualified applicants, according to a ...